Founded in 2015, Inova Pharma & Life Science is a private, revenue-generating Irish CDMO offering end-to-end development and manufacturing services for pharmaceutical clients worldwide. The company's core expertise lies in developing value-added medicines and super-generics across a wide range of therapeutic areas, supported by a full suite of analytical, formulation, and regulatory services compliant with cGMP/GLP standards. Inova positions itself as a partner for navigating the complex path from development to commercialization, leveraging strategic partnerships for additional support in marketing and design.
Cardiovascular systemGastroenterologyPain management and RheumatologyAntibiotics & Infectious DiseasesUrinary systemDiabetic molecules & EndocrineENT & RespiratoryNeuroscience ResearchOncologyOphthalmologyPaediatrics medicinesBiotechnology developmentNephrology and Renal Diseases
Technology Platform
Integrated CDMO service platform offering formulation development (oral solids, sterile, potent compounds), analytical method development/validation, stability testing, cGMP/GLP-compliant manufacturing scale-up, and full regulatory support for 505(b)(2) and super-generic pathways.
Funding History
2
Total raised:$25.2M
Series A$22MFountain Healthcare Partners
Seed$3.2MEnterprise Ireland
Opportunities
Growing demand for super-generics and 505(b)(2) product development provides a strong tailwind for its specialized services.
Its end-to-end service model and EU base position it well to serve virtual and small biotech companies seeking a single, agile partner for complex development programs.
Risk Factors
Faces intense competition from larger, global CDMOs and niche players.
Revenue is dependent on client project success and biotech funding cycles.
Operational reputation is critical; any significant quality or regulatory failure could severely impact the business.
Competitive Landscape
Inova competes in the fragmented global CDMO market, contending with large, full-service giants (e.g., Lonza, Catalent, Thermo Fisher) and numerous specialized smaller firms. Its differentiation hinges on agility, a focus on value-added medicines/super-generics, and an integrated service offering that includes regulatory and commercial design support via partnership.
